![The Commercial Use of Biodiversity]( "The Commercial Use of Biodiversity")
Click to have a closer look
About this book
Contents
Biography
Related titles
About this book
Explains the International Convention on Biological Diversity (CBD) and its provisions on access and benefit sharing. A sector by sector analysis is also provided for the following industries: Pharmaceuticals; Biotechnology; Agriculture and crop protection; Horticulture; Botanical medicines and neutraceuticals; Personal care products and cosmetics.
Contents
Introduction - Regulating Access to Genetic Resources and Benefit-sharing: The Legal Aspects - Natural Products and the Pharmaceutical Industry - The Botanical Medicine Industry - Development of Major Crops by the Seed Industry - Horticulture - Crop Protection - Biotechnology in Fields other than Healthcare and Agriculture - The Natural Personal Care and Cosmetics Industry - Industry and the CBD - Conclusions - Glossary, Bibliography, Index
Customer Reviews
Biography
Kerry ten Kate is Policy Adviser for the Directorate of, and Sarah Laird is Independent Consultant for the Convention on Biodiversity Unit at, the Royal Botanic Gardens, Kew
By: Kerry Ten Kate and Sarah A Laird
398 pages, Figs, tabs
'Written by two of the world's leading authorities on the commercial use of biodiversity, this book is an invaluable resource and guide for further research. It is as practical as it is informative and should be in the hands of everyone interested in the state and fate of the world's living resources' Professor Calestous Juma, Harvard University 'Full of examples from which we can learn... this will be an invaluable resource to policy-makers, organizations studying and creating uses for genetic resources and the companies which wish to develop them' from the Foreword by Professor Sir Ghillean Prance, ex-Director, Kew Gardens and Sir Richard Sykes, ex-Chairman, Glaxo Wellcome
